Fed. Circ. Gives Bayer Chance To Save Xarelto Patent Claims
The Federal Circuit revived several claims of a patent underpinning Bayer Pharma Aktiengesellschaft's blockbuster blood thinner Xarelto on Tuesday, sending the challenge brought by Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA Inc....To view the full article, register now.
Already a subscriber? Click here to view full article